DNA Polymerase Fidelity, Processivity and Inhibitor Tolerance

Match each property to the question it can answer

Polymerase selection becomes clearer when the biochemical property and the application endpoint are kept separate. A fidelity experiment counts copying errors. A processivity experiment examines extension before dissociation. An inhibition experiment challenges a reaction with specified material. These experiments can inform the same assay, but their outputs are not interchangeable.

A PCR result adds further layers: primer binding, template accessibility, thermal cycling, formulation and detection. Product quantity integrates many of those effects. Treat a good amplification result as evidence that the tested combination worked, then use a more specific experiment if the cause of that performance matters.

Avoid converting these properties into a single quality score without explaining the assay requirement. A small difference in error rate may matter greatly for one sequencing workflow, while a change in detection reliability across sample backgrounds may dominate another decision. A useful comparison preserves the separate evidence and makes the priority explicit.

Read fidelity claims through the measurement method

Fidelity concerns the accuracy of DNA synthesis. Nucleotide selection limits incorrect incorporation, and proofreading by a 3′→5′ exonuclease can remove misincorporated nucleotides. Proofreading is one contributor to accuracy; its presence alone is not a complete fidelity measurement. It is also distinct from the 5′ nuclease activity used in some probe-based detection systems.

Cline and colleagues compared thermostable polymerases and investigated reaction conditions. Their results showed that proofreading status and buffer conditions could substantially affect measured error rates. Consequently, an error-rate claim belongs to the enzyme and the conditions used to measure it. Moving the enzyme into a different formulation requires evidence that the relevant behavior is retained.

Check the denominator before comparing numbers. Errors per base in a final product population, errors per base per template doubling, and errors normalized to programmed PCR cycles describe different quantities. A thermal cycle need not produce a complete doubling of the target. Potapov and Ong discuss this distinction and its effect on comparisons between studies.

The detection method matters too. A reporter assay measures mutations that alter its readout, while sequencing can examine changes across the sequence space actually covered. McInerney and colleagues used sequencing of cloned PCR products across multiple targets and highlighted the difficulty of comparing studies with different methods. Their findings support examining mutation spectra and experimental coverage alongside an average error rate.

When reviewing a fidelity report, ask which substitutions and insertions or deletions were counted, how many independent observations supported the estimate, and how background errors were assessed. A result with no detected errors has a detection limit. It does not demonstrate an enzyme that never makes a mistake. Likewise, small numerical differences are not persuasive without uncertainty and adequate sampling.

Keep copying accuracy distinct from primer specificity. A polymerase can accurately copy an unintended amplicon. A clean band or an apparently specific fluorescent signal therefore cannot replace an error measurement when sequence preservation is the objective. Conversely, a low error rate does not establish that a diagnostic reaction excludes related organisms or closely matched non-target sequences.

Separate processivity from speed and amplicon length

Processivity describes the extent of synthesis during one association-dissociation cycle with the primer-template. Extension rate describes the pace of synthesis over time. An enzyme can remain associated for many incorporations without being the fastest enzyme under another set of conditions. Report which property was measured rather than using “fast” and “processive” as synonyms.

Bedford, Tabor and Richardson demonstrated how transferring a thioredoxin-binding domain could confer greater processivity on a chimeric polymerase when the interacting protein was present. This provides a mechanistic example of how sustained association can change synthesis. It does not imply that the same accessory system should be added to a diagnostic PCR.

For thermostable polymerases, Wang and colleagues showed that fusion to a non-sequence-specific DNA-binding protein could increase processivity and improve PCR performance in their tested systems. Their work also illustrates why a processivity claim should be accompanied by an appropriate biochemical measurement, rather than inferred only from a brighter PCR band.

A measurement intended to represent one binding event must address rebinding. If dissociated enzyme can repeatedly return to the same substrate, the final extension length may reflect several encounters. Ask how the method limited or tested that possibility. Also retain the substrate, temperature, reaction composition and analysis definition when comparing reported values.

Maximum PCR product length is an application result. During a reaction, repeated enzyme binding can contribute to extension, and success also depends on template integrity and reaction conditions. Thus a polymerase with a modest single-event extension length can still support a much longer PCR product. The two lengths should not be equated.

For a long-target or short-extension workflow, first test whether the candidate completes the intended amplicon under the actual program. Record product identity and completeness as well as yield. If the result improves, describe that application improvement directly. Reserve a mechanistic explanation such as increased processivity for evidence that specifically supports it.

Define the inhibitor challenge before ranking enzymes

Inhibitor tolerance is an operational comparison: how well does a defined reaction retain its required performance when a specified interfering material is present? Name the challenge, its final amount in the reaction, the target input and the endpoint. A tolerance claim without those details gives little basis for transferring the result to another assay.

Kermekchiev and colleagues demonstrated that polymerase mutations could improve amplification in the presence of selected blood- and soil-associated inhibitors. Their experiments establish that enzyme structure can influence tolerance. They do not establish that a candidate selected with one inhibitor will perform equally well with every sample matrix or preserve every other enzyme property.

A matrix may affect more than catalytic activity. Sidstedt and colleagues found that blood-associated components could influence polymerase activity, DNA interactions and fluorescence. In their tested systems, hemoglobin affected amplification and quenched fluorescence, while immunoglobulin G interacted with single-stranded genomic DNA. A weak optical signal therefore needs interpretation before it is attributed to poor enzyme tolerance.

For candidate screening, compare challenged and clean reactions at controlled target input and retain unsuccessful replicates in the analysis. Decide in advance whether the meaningful endpoint is detection frequency, product yield, quantitative bias or another assay-specific measure. A reaction that remains positive can still be unsuitable for quantitative use if the matrix shifts its measurement.

Separate the enzyme from the formulation in the conclusion. If complete mixes differ, the result compares complete mixes. Additives, salts and other components may contribute to the outcome. The Direct PCR and Sample-Tolerant Enzyme Guide develops the sample-handling and matrix-study design in more detail, including the difference between testing downstream inhibition and testing release of the native target.

Set priorities according to how the product will be used

The most useful selection question is which failure would invalidate the intended result. That question determines the first evidence to request and the other constraints that still need confirmation. The examples below are starting points for development, not a universal ranking of enzyme families.

These priorities can overlap. An amplification step that precedes variant analysis may need both low copying error and adequate recovery from challenging specimens. A rapid assay may need completion within a constrained extension interval without sacrificing detection reliability. Evaluate that combination instead of assuming that one favorable property resolves the whole requirement.

Do not infer a universal trade-off either. Evidence of improved processivity does not by itself imply lower fidelity, and evidence of inhibitor resistance does not establish a fidelity penalty. Equally, absence of a reported penalty is not evidence that all other properties were preserved. Measure the combination that matters.

For sequence-sensitive applications, consider errors beyond base misincorporation. Potapov and Ong examined template switching, recombination and DNA damage as additional sources of altered PCR products. Their study supports evaluating the complete amplification workflow when interpreting sequence artifacts, rather than attributing every observed change to the polymerase active site.

Detection chemistry can also rule out an otherwise attractive candidate. Establish required catalytic activities and reagent compatibility before extensive ranking. The PCR and qPCR Enzyme Selection Guide covers those PCR-specific choices, while the Molecular Diagnostic Enzyme Selection Guide places them within the broader molecular workflow.

Build a comparison that supports a bounded decision

Use a short evidence record for each candidate. For fidelity, retain the method, error categories, denominator, reference enzyme and uncertainty. For processivity, retain the single-binding-event logic and substrate conditions. For tolerance, retain the challenge composition and the analytical endpoint. Mark a property as unmeasured when the available evidence does not address it.

Distinguish a replacement test from a search for the best achievable formulation. Holding the established assay conditions constant asks whether a candidate can replace the current reagent. Optimizing each candidate asks a different question. Both are useful, but combining the results without identifying the design can create a misleading enzyme ranking.

Then confirm the selected combination in the intended assay. Include representative targets, relevant sample backgrounds and conditions near the assay's difficult operating boundary. Reassess the endpoints that drove the choice after meaningful formulation changes. A buffer adjustment that improves amplification is a reason to check sequence accuracy when accuracy is a critical requirement.

Document the basis for selection in direct terms: the formulation tested, the target and sample conditions covered, the observed application endpoint, and the important gaps. Keep literature evidence separate from your own measurements. Neither a historical polymerase comparison nor a biochemical specification establishes the analytical or clinical performance of a finished diagnostic test.

The resulting decision should explain why the enzyme fits this application and what still needs confirmation. Related assay and formulation topics are collected in the Molecular Diagnostic Enzyme and Master Mix Guides hub. Use the three properties as distinct sources of evidence throughout development, rather than allowing a single descriptive label to stand in for the complete evaluation.